0001209191-23-034695.txt : 20230605 0001209191-23-034695.hdr.sgml : 20230605 20230605213809 ACCESSION NUMBER: 0001209191-23-034695 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210622 FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daly James M CENTRAL INDEX KEY: 0001560782 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 23994740 MAIL ADDRESS: STREET 1: INCYTE CORPORATION EXPERIMENTAL STATION STREET 2: RTE 141 & HENRY CLAY RD. BLDG E336 CITY: WILMINGTON STATE: DE ZIP: 19880 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2021-06-22 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001560782 Daly James M C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130 1 0 0 0 0 Common Stock 2021-06-22 4 M 0 3059 A 3059 D Common Stock 2022-06-07 4 M 0 6391 A 9450 D Common Stock 2023-06-01 4 M 0 8552 A 18002 D Restricted Stock Units 2021-06-22 4 M 0 3059 0.00 D Common Stock 3059 0 D Restricted Stock Units 2022-06-07 4 M 0 6391 0.00 D Common Stock 6391 0 D Restricted Stock Units 2023-06-01 4 M 0 8552 0.00 D Common Stock 8552 0 D Director Stock Options (Right to Buy) 23.90 2023-06-01 4 A 0 11045 0.00 A 2033-05-31 Common Stock 11045 11045 D Restricted Stock Units 2023-06-01 4 A 0 6652 0.00 A Common Stock 6652 6652 D Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date. The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date. /s/ Austin D. Kim, Attorney-in-Fact 2023-06-05